Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
Cocaine use disorders affect approximately 1.5 million Americans annually. Currently, there
are no US Food and Drug Administration approved medications for treatment of cocaine
dependence; however, both animal and human studies suggest that medications affecting the
noradrenergic system can reduce cocaine craving and use. The investigators will study the
effect of doxazosin, an alpha-1 adrenergic antagonist, in reducing cocaine use and anxiety
symptoms among cocaine-dependent individuals. In addition, the investigators will identify
genetic subpopulations of participants who preferentially respond to the medication.